Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Veracyte Inc (NQ: VCYT )

40.37 +0.78 (+1.97%)
Streaming Delayed Price Updated: 12:03 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules
From Veracyte, Inc.
Via Business Wire
Better Long-Term Buy in 2023: Exact Sciences or Veracyte?
As cancer screenings are becoming covered more often, both companies stand to gain. 
Via The Motley Fool
Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
From Exagen Inc.
Via GlobeNewswire
Expert Ratings for Veracyte
Via Benzinga
Veracyte Earnings Perspective: Return On Capital Employed
Via Benzinga
Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
Via Benzinga
This Small-Cap Stock Is a No-Brainer Buy
This genomic test maker's stock was beaten down in 2022. But it could be heading for a rebound this year. 
Via The Motley Fool
Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis
From Veracyte, Inc.
Via Business Wire
Veracyte Stock Showing Market Leadership; Earns 93 RS Rating
Veracyte shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
US Stocks Open Lower; Nasdaq Drops 100 Points
U.S. stocks traded lower this morning, with the Nasdaq Composite dropping around 100 points on Thursday. The Federal Reserve, on Wednesday, raised interest rates by 75 bps. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry. 
Via Benzinga
Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60. 
Via Benzinga
Veracyte Announces Third Quarter 2022 Financial Results
From Veracyte, Inc.
Via Business Wire
Earnings Scheduled For November 2, 2022
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter. 
Via Benzinga
Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting
From Veracyte, Inc.
Via Business Wire
Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference
From Veracyte, Inc.
Via Business Wire
New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy
From Veracyte, Inc.
Via Business Wire
Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer
From Veracyte, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers ASLAN Pharma (NASDAQ:ASLN) stock moved upwards by 13.7% to $0.54 during Wednesday's after-market session. The market value of their outstanding shares is at $37.6 million. 
Via Benzinga
New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
From Veracyte, Inc.
Via Business Wire
Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022
From Veracyte, Inc.
Via Business Wire
New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men
From Veracyte, Inc.
Via Business Wire
Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access
From Veracyte, Inc.
Via Business Wire
New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer
From Veracyte, Inc.
Via Business Wire
New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy
From Veracyte, Inc.
Via Business Wire
Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From Veracyte, Inc.
Via Business Wire
Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022
From Veracyte, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.